胞苷脱氨酶状态作为MDS和AML患者对阿扎胞苷治疗反应的标志物
研究探讨真实世界成人患者中胞苷脱氨酶(CDA)表型与阿扎胞苷(Aza)毒性及疗效的关联。AML和高危MDS患者中位总生存期分别为15个月和13个月。半数患者CDA活性缺陷(<2 UA/mg),MDS患者中CDA缺陷比例为34%,AML患者为67%。在MDS患者中,CDA缺陷与更长的界标总生存期相关(14 vs 8个月;p=0.03),但在AML患者中无此关联。数据提示CDA是独立协变量,可能作为预测MDS患者接受Aza治疗临床结局的标志物。
要点
- AML和高危MDS患者中位总生存期分别为15个月和13个月。
- MDS患者CDA缺陷比例为34%,AML患者为67%。
- MDS患者中CDA缺陷与更长的界标总生存期相关(14 vs 8个月;p=0.03),AML患者中无此关联。
核心结论
- 数据提示CDA是独立协变量,可能作为预测MDS患者接受Aza治疗临床结局的标志物。
- 数据提示延迟Aza治疗与疗效缺乏无关,不应被视为更换替代治疗的信号。
研究设计与样本
- 研究为真实世界成人患者研究,探讨CDA表型与Aza毒性及疗效的关联。
主要发现
- AML和高危MDS患者中位总生存期分别为15个月和13个月。
- 半数患者CDA活性缺陷(<2 UA/mg),MDS患者中缺陷比例为34%,AML患者为67%。
- MDS患者中CDA缺陷与更长的界标总生存期相关(14 vs 8个月;p=0.03),AML患者中无此关联。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Azacitidine (Aza) is a mainstay of treatment for patients with acute myeloid leukaemia (AML) ineligible for induction chemotherapy and other high-risk myelodysplastic syndromes (MDS). Only half of patients respond, and almost all will eventually relapse. There are no predictive markers of response to Aza. Aza is detoxified in the liver by cytidine deaminase (CDA). Here, we investigated the association between CDA phenotype, toxicity and efficacy of Aza in real-world adult patients. Median overall survival (OS) was 15 months and 13 months in AML and high-risk MDS patients respectively. In addition, our data suggest that delaying Aza treatment was not associated with lack of efficacy and should not be considered a signal to switch to an alternative treatment. Half of the patients had deficient CDA activity (i.e. <2 UA/mg), with a lower proportion of deficient patients in MDS patients (34%) compared to AML patients (67%). In MDS patients, CDA deficiency correlated with longer landmark OS (14 vs. 8 months; p = 0.03), but not in AML patients. Taken together, our data suggest that CDA is an independent covariate and may therefore be a marker for predicting clinical outcome in MDS patients treated with Aza.
引用
- Donnette M, Hamimed M, Ciccolini J, et al. Cytidine deaminase status as a marker of response to azacytidine treatment in MDS and AML patients. Br J Haematol. 2023. PMID: 37691342. doi:10.1111/bjh.19096
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。